Duc has been an employee to Step Pharma since March 2020 acting as Chief Development Officer.
He brings over twenty years of experience in drug discovery and drug development for big pharma companies (Sanofi-Aventis, Pfizer, Lundbeck) and biotech start-ups (Preglem, Arisgen, EspeRare, Prexton Therapeutics).
Duc’s experience extends across many therapeutic areas including cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease and reproductive medicine. He has successfully delivered a number of projects into clinical development and on to registration. Duc is responsible for the drug development programs, providing pre-IND non-clinical, CMC and clinical leadership, implementing regulatory strategy, to ensure successful transition of lead candidates into clinical development.
Duc graduated from the French Grandes Ecoles d’ingénieurs ESPCI in Physics, Chemistry and Biology. Duc also holds a MSc degree in organic and bioorganic chemistry from Paris VI and is a registered Project Manager.
About Step Pharma
Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of cancer types. The company has identified several inhibitors of CTPS1, with the most advanced, STP938, being prepared for clinical studies in haematological malignancies.
Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Dr Sylvain Latour and Prof. Alain Fischer (UMR1163 Inserm unit). Step Pharma is based in Saint-Genis-Pouilly, France, and is supported by a strong investor base led by Kurma Partners and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares and InnoBio2 Fund), Pontifax, Hadean Ventures, Sunstone Life Science Ventures, Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute.
For more information please contact
Andrew Parker, Chief Executive Officer